<DOC>
	<DOCNO>NCT02257476</DOCNO>
	<brief_summary>The purpose study find safe dose level approve drug , carfilzomib , solid tumor give different period time normally use . The study also use marker blood routine blood draw help check level drug . Lastly , study check well drug work regard keep cancer cell grow new time frame delivery .</brief_summary>
	<brief_title>Extended Infusion Carfilzomib Weekly Schedule Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The role proteasome carcinogenesis cell survival well establish , inhibition associate accumulation pro-apoptotic protein cell death . Proteasome inhibitor , bortezomib , extensively study widely use effective therapy treatment hematologic malignancy , multiple myeloma circulate proteasome level correlate survival . Carfilzomib , novel irreversible proteasome inhibitor specifically target chymotryptic site proteasome show potency bortezomib may able overcome bortezomib resistance . Response rate 25-54 % see patient previously treat myeloma phase 2 setting . Given effectiveness proteasome inhibition multiple myeloma , role proteasome solid tumor active investigation . Previous trial bortezomib breast , prostate , lung , pancreatic cancer show little activity agent disease . Whether lack activity may mechanistically relate ( bortezomib inhibits chymotrypsin-like peptidyl-glutamyl peptide-hydrolyzing ( PGPH ) -like activity proteasome ) , lack potency target inhibition , unknown . In phase Ib/II study 14 patient ( phase I ) 51 patient ( phase II ) advance solid tumor , Rosen colleague note single-agent activity carfilzomib . Carfilzomib dose day 1 , 2 , 8 , 9 , 15 , 16 28 day cycle maximum 12 cycle , 20-36 mg/m² note recommended phase 2 dose base DLT data . A PR renal small cell lung cancer , stable disease &gt; 16 week mesothelioma , ovarian , renal , non-small cell lung cancer observe . The treatment tolerable common adverse event ( AEs ) include fatigue , headache , diarrhea , nausea constipation . Given activity carfilzomib see select solid tumor , unpublished data suggest weekly dosing may result similar pharmacokinetic profile include AUC , investigator propose study safety , tolerability , pharmacokinetics , anti-tumor activity carfilzomib monotherapy give weekly dosing schedule . Weekly dosing advantage patient convenience , acceptable toxicity pharmacokinetics , allow easy integration schedule subsequent combination therapy clinical trial .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient age 18 year old time enrollment . Advanced/metastatic solid tumor refractory standard therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . Adequate organ function assess follow : Bone marrow : Hemoglobin great equal 9.0 g/dL Absolute neutrophil count ( ANC ) great equal 1,500/mm³ Platelet count great equal 100,000/mm³ Hepatic : Total bilirubin less equal 1.5 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x ULN Prothrombin time ( PT ) international normalize ratio ( INR ) /partial thromboplastin time ( PTT ) &lt; 1.5 x ULN except patient receive active anticoagulation Renal : Serum creatinine ≤ 1.5 x upper limit normal Glomerular filtration rate ( GFR ) 50 ml/minute great ( elevate serum creatinine level &gt; 1.5 x ULN ) Willingness sign inform consent patient patient 's legal representative . Patient know adequately treated brain metastasis without central nervous system ( CNS ) disease progression determine CT MRI image within 4 week first dose study drug . Treatment related residual toxicity &gt; grade 1 . Prior treatment proteasome inhibitor . Uncontrolled systemic disease intercurrent illness . Recent history myocardial infarction ( MI ) symptomatic coronary artery disease within precede 6 month . History uncontrolled hypertension ( systolic &gt; 150 mmHg diastolic pressure &gt; 90 mmHG despite optimal medical management ) . Ejection fraction &lt; 50 % . Known actively treat infection human immunodeficiency virus ( HIV ) , hepatitis B C. Major surgery significant traumatic injury within 4 week first study treatment subject fully recover . Pregnant breast feed woman . Female patient childbearing potential male patient partner childbearing potential unable unwilling use effective contraception ( double barrier condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ; hormonal method oral , parenteral transdermal hormonal agent least three month prior study drug administration ) . Corticosteroid dos great equivalent prednisone 7.5 mg PO daily . Recent therapy active anticancer agent within 4 week 1st dose study drug . Any current malignancy previous malignancy within 3 year enrollment except : curatively treat situ carcinoma cervix uterus ; localize basal squamous cell carcinoma skin , curatively treat situ breast carcinoma , early stage prostate cancer . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior randomization . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>carfilzomib</keyword>
	<keyword>advanced solid malignancy</keyword>
	<keyword>advanced solid cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>bladder</keyword>
	<keyword>colon</keyword>
	<keyword>breast</keyword>
	<keyword>lung</keyword>
</DOC>